Lorbrena (lorlatinib) — Medica
Non-Small Cell Lung Cancer – Anaplastic Lymphoma Kinase (ALK)-positive
Initial criteria
- Patient is age ≥ 18 years
- Patient has advanced or metastatic disease
- Patient has anaplastic lymphoma kinase (ALK)-positive disease
- The mutation was detected by an approved test
Approval duration
1 year